Evidence map›Paper›PMID 31977876›Full record

Observational studyMedicine2020

Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma.

Xinjian Yan, Tianyu Wu, Mei Tang, Dongliang Chen, Meiyuan Huang, Sichun Zhou, Huihui Zhang, Xiaoping Yang, Gaofeng Li

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xinjian YanDepartment of Medical Oncology Department of Pathology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan.
Tianyu WuDepartment of Medical Oncology Department of Pathology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan.
Mei TangDepartment of Medical Oncology Department of Pathology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan.
Dongliang ChenDepartment of Medical Oncology Department of Pathology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan.
Meiyuan HuangDepartment of Medical Oncology Department of Pathology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan.
Sichun ZhouKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, Hunan, China.
Huihui ZhangKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, Hunan, China.
Xiaoping YangKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, Hunan, China.
Gaofeng LiDepartment of Medical Oncology Department of Pathology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan.
Zhuzhou Central Hospital · CNHunan Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this study was to evaluate the contribution of ataxia telangiectasia mutated (ATM) gene promoter methylation to hepatocellular carcinoma (HCC) and the predictive value of radiotherapy outcome. ATM promoter methylation status was detected using methylation-specific PCR in 118 HCC, 50 adjacent liver, and 20 normal liver samples. PCR products were verified by bisulfite sequencing PCR. ATM expression was detected by quantitative PCR (qPCR) and immunohistochemistry (IHC) in 50 paired HCC and adjacent normal tissues and 68 locally advanced HCC biopsy tissues. Furthermore, radiotherapy outcomes in 68 locally advanced HCC patients were determined using European Association for the Study of Liver criteria and survival analysis. The results revealed that the methylation frequency of the ATM promoter was significantly higher in HCC tissues than in normal liver tissues (χ = 16.830, P < .001). Quantitative PCR (qPCR) and IHC results showed a significant association between ATM promoter methylation and ATM expression in HCC (χ = 10.510, P < .001), and methylated ATM was correlated with lower ATM expression compared with unmethylated ATM (r = 0.356, P < .001). Furthermore, methylation of the ATM promoter was significantly associated with superior outcomes in patients with locally advanced HCC who initially received radiotherapy. Together, these results indicate that ATM promoter methylation might increase the risk of HCC by regulating ATM expression, and thus may function as a potential biomarker for predicting radiotherapy outcomes in HCC patients.

Indexed as

Ataxia Telangiectasia Mutated ProteinsDNA MethylationAdultAgedBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiddle AgedMutationPredictive Value of TestsReal-Time Polymerase Chain ReactionAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkers, Tumor

Identifiers

PMID31977876
PMCPMC7004781
OpenAlexW3002488478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.